Foghorn reports Q2 net loss $23M; cash $285M into 2027; FHD-286 AML data Q4; FHD-909 first patient H2 2024

Foghorn Therapeutics Inc.

2024-Q2 EPS reported -$1.02 revenue$11,938,000

Net loss $23.0M for Q2 2024 vs $29.5M in Q2 2023; collaboration revenue $6.9M.
Cash, equivalents & marketable securities $285.2M as of June 30, 2024; expected cash runway into 2027.
Topline Phase 1 data for FHD-286 + decitabine in r/r AML anticipated Q4 2024; includes safety, efficacy, PK/PD.
FHD-909 (SMARCA2 selective inhibitor) IND cleared May 2024; first patient dosing H2 2024 in SMARCA4 mutated NSCLC.
Selective CBP degrader IND-enabling studies on track to start Q4 2024; $110M financing closed May 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.